BioMed Research International

BioMed Research International / 2015 / Article

Research Article | Open Access

Volume 2015 |Article ID 938747 |

Saeed S. Al-Sokari, Nasser A. Awadh Ali, Lianet Monzote, Mohamed A. Al-Fatimi, "Evaluation of Antileishmanial Activity of Albaha Medicinal Plants against Leishmania amazonensis", BioMed Research International, vol. 2015, Article ID 938747, 6 pages, 2015.

Evaluation of Antileishmanial Activity of Albaha Medicinal Plants against Leishmania amazonensis

Academic Editor: Yu-Ping Tang
Received01 Jul 2015
Accepted04 Aug 2015
Published19 Aug 2015


Sixteen methanolic extracts obtained from thirteen plant species, selected either from ethnobotanical or chemotaxonomical data, were screened for their antileishmanial activity against Leishmania amazonensis. The cytotoxic activity against normal peritoneal macrophages from normal BALB/c mice was also determined. Eight extracts had IC50 values ranging from <12.5 to 37.8 µg/mL against promastigotes. Achillea biebersteinii flower, Euphorbia helioscopia, and Solanum incanum leaf extracts showed antileishmanial activities with IC50 between <12.5–26.9 µg/mL and acceptable selectivity indices of 8–5. The other leishmanicidal plant extracts, with IC50 ranging from 18.0 to 29.5 µg/mL, exhibited low selectivity indices.

1. Introduction

Leishmaniasis is distributed worldwide, especially in tropical and subtropical areas and more than 12 million people are currently infected. About 20 000 to 30 000 deaths occur annually. Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis and causes skin lesions, mainly ulcers. About 95% of CL cases occur in the Americas, the Mediterranean basin, the Middle East, and Central Asia. Over two-thirds of new CL cases occur in 6 countries: Afghanistan, Algeria, Brazil, Colombia, Iran, and Syria. An estimated 0.7 million to 1.3 million new cases occur worldwide annually [1, 2].

In Saudi Arabia, the disease was first described in 1973 by Morsy and Shoura [3]. Currently, CL is common in the human population in different localities, including the Eastern Province of Saudi Arabia and in particular the Al-Hassa Oasis that is a known endemic area for CL [4]. At the moment, no good conventional treatments for CL in most countries are available. The conventional drugs are very toxic and not 100% effective. Therefore, there is an urgent need to discover new therapeutic agents. Traditional medicine knowledge can be useful to open new ways in the search of new antileishmanial agents. A number of published studies have demonstrated that many plant extracts exhibited activity against Leishmania parasites [58]. Some reports were published about the antiprotozoal activity of Saudi medicinal plants [5, 911]. In this study, the plant species were selected either from ethnobotanical or chemotaxonomical data [12]. It is noteworthy to mention that to the best of our knowledge, this study represents the first report on antileishmanial activity for some of the tested plants. The aim of this study was to investigate the antileishmanial activity of the 16 methanol extracts from 13 selected plant species from Albaha region, against Leishmania amazonensis.

2. Material and Methods

2.1. Plant Materials

The plant material was collected in March-April 2014 from different locations in Albahah town and outskirts of Albaha, except myrrh oleo gum resins that were purchased from the herbal shops under the name (Somali Myrrha) (Table 1). The plants were taxonomically identified at the Faculty of Science, Department of Botany, Aden University, Yemen. Voucher specimens of the plant material are deposited at the Pharmacognosy Department, Faculty of Clinical Pharmacy, Albaha University, Saudi Arabia.

SpeciesPlant family (voucher specimen no)Part testeda (yield in %)Local nameTraditional uses

Achillea biebersteinii Afan.Asteraceae (CP-101)Fl (1.5)ThafraAntispasmodic and for1 kidney inflammation

Achillea biebersteinii Afan. (CP-101)L (2.6)ThafraAs antispasmodic and for kidney inflammation

Calotropis procera (Aiton) W.T.AitonAsclepiadaceae (CP-091)L (4.2)AlashurFor treating leprosy and filariasis

Chenopodium murale L.Amaranthaceae (CP-081)F (7.3)JkhearaLeishmaniasis1

Commiphora myrrha L.Burseraceae (CP-071)Resin (70)Somali mirGum used for treating leishmaniasis2

Dodonaea viscosa Jacq.Sapindaceae (CP-061)L (3.5)ShathFor treating chronic ulcer, burns, leishmaniasis2

Euphorbia helioscopia L.Euphorbiaceae (CP-051)AP (4.2)Al-dehinAntiseptic

Lavandula dentata L.Lamiaceae (CP-041)AP (2.9)Al-shiahAs antispasmodic, antiseptic when the leaves chewed1

Pulicaria crispa SCH.BIP Asteraceae (CP-102)AP (3.1)ArararabiAntimalarial, stomach disorders2

Punica granatum L. Punicaceae (CP-011)Fl (2.5)Al-romanAnthelmintic, antiseptic2

Ruta chalepensis L.Rutaceae (CP-121)L (5.2)Al-shathabAntimicrobial2

Solanum incanum L.Solanaceae (CP-131) F (7.6)Al-hadakAntiseptic2

Solanum incanum L.Solanaceae (CP-132)L (3.9)Al-hadakLeaves as dressing for healing wounds, paste of fruits for treating leishmaniasis2

Verbesina encelioides (Cav.) Benth & Hook. f. ex A. GrayAsteraceae (CP-021)L (3.7)SafearaWounds, skin diseases2

Withania somnifera (L.) DunalSolanaceae (CP-011)F (4.6)AlobebChronic dermatitis2

Withania somnifera Solanaceae (CP-011)L (8.5)Alobeb

AP, aerial parts; F: fruits; L: leaves; Re: resins; Fl: flowers: 1most information obtained from reference [12] and 2interviewing with local people.
2.2. Preparation of Extracts

Air-dried and powdered plant material (10 g) was extracted under shaking at room temperature with MeOH (4 × 100 mL). The obtained extracts were filtered and evaporated to dryness in vacuo at 40°C. The yields of each dried extract were calculated in %. The resulting dried crude extracts were stored at 4°C. For testing, the extracts were dissolved in dimethylsulfoxide (DMSO) at 20 mg/mL.

2.3. Antileishmanial and Cytotoxicity Assays
2.3.1. Parasite Cultures

Strain MHOM/77BR/LTB0016 of L. amazonensis, provided by Immunology Department at Oswaldo Cruz Foundation (FIOCRUZ) from Brazil, was used. Parasites were routinely isolated from normal BALB/c mice lesions and maintained as promastigotes at 26°C in Schneider’s medium (SIGMA, St. Louis, MO, USA) containing 10% heat-inactivated fetal bovine serum (HFBS) (SIGMA, St. Louis, MO, USA) and corresponding antibiotics (100 μg of streptomycin/mL, 100 U penicillin/mL). Parasites were not used after the tenth passage to carry out in vitro experiments.

2.3.2. Antipromastigote Assay

Fifty microliters of Schneider’s medium with HFBS and antibiotics was distributed in each well of a 96-well plate. In the first one, additional 48 μL of medium was added as well as 2 μL of extracts. Then, five dilutions 1 : 2 were carried out taking 50 μL each time to test concentrations of the extracts ranging from 12.5 to 200 μg/mL and a final volume was completed to 100 μL after addition of 50 μL of parasites at 4 × 105 promastigotes/mL in logarithmic phase. Also, parasites treated with DMSO or pentamidine (Richet, Buenos Aires, Argentina) were also included as controls. Plates were sealed with parafilm and incubated at 26°C during 72 hours. Then, 20 μL of a solution of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (SIGMA, St. Louis, MO, USA) at 5 mg/mL prepared and filtered in the moment of use was added in each well. An additional incubation of 4 hours was performed, the supernatant was eliminated, and the formazan crystals were dissolved with 100 μL of DMSO. The optical density was determined using a spectrophotometer (Sirio S Reader, 2.4-0, Italy), at a test wavelength of 560 nm, using 630 nm as reference wavelength [13, 14]. The median inhibitory concentration (IC50) was obtained from linear dose-response curves fit to data by means of the linear equation model. The evaluations were performed in triplicate and the results are expressed as mean ± standard deviation.

2.3.3. Cytotoxicity Assay

The cytotoxic median concentration (CC50) of the extracts was also determined on normal peritoneal macrophages from normal BALB/c mice [13]. Resident macrophages were collected from peritoneal cavities of animals in ice RPMI 1640 medium (SIGMA, St. Louis, Mo, USA) supplemented with antibiotics. Suspension was seeded at 30000 cells/well and incubated for 2 hours at 37°C in 5% CO2. Nonadherent cells were removed by washing and 50 μL of medium complemented with 10% of HFBS and antibiotics was added. Additional 48 μL was distributed in first well along with 2 μL of tested extracts. Plant extracts were tested at 5 concentrations (200, 100, 50, 25 and 12.5 μg/mL) to establish a full dose-titration and determination of the IC50 (inhibitory concentration 50%). The plate was incubated under the same conditions during 72 hours. Macrophages treated with DMSO or pentamidine were included as controls. Cells viability was determined using the colorimetric assay with MTT as previously described, where 15 μL was added to each well, and CC50 was obtained from dose-response curves fit to data by means of the linear equation model. The evaluations were performed in triplicate and the results are expressed as mean ± standard deviation.

Then, the selectivity index (SI) ratio was obtained from calculation: CC50 for macrophage/IC50 for promastigotes [15]. Extracts with SI ≥ 5 or with IC50 < 12.5 μg/mL against promastigotes were selected for further experiments.

2.3.4. Antiamastigote Assay

The peritoneal macrophages were obtained as previously described and plated at 106/mL in 24-Well Lab-Tek (Costar, USA). Nonadherent cells were removed by washing after incubation of 2 hours at 37°C in 5% CO2. Macrophages were then infected with stationary-phase of L. amazonensis promastigotes at 4 : 1 parasite/macrophage ratio and incubated again during 4 hours at the same conditions. Free parasites were removed by washing and 1000 μL of RPMI completed medium was added in each well. In the first well, additional 990 μL of medium and 10 μL of the tested extracts were added and four dilutions 1 : 2 were carried out taking 1000 μL each time, testing final concentrations between 12.5 and 100 μg/mL. The plate was incubated at the same conditions for 48 hours [16]. Then, monolayer was fixed in absolute methanol, stained with Giemsa, and examined under light microscopy. Number of intracellular amastigotes and percent of infected macrophage were determined by counting 25 macrophages per sample, and the results were expressed as percent of reduction of the infection rate (obtained by multiplying the percentage of infected macrophages by the number of amastigotes per infected macrophages) in comparison to controls [15]. IC50 value was determined from the concentration-response linear curves. The evaluations were performed in triplicate and the results were expressed as mean ± standard deviation.

3. Results and Discussion

Sixteen methanolic extracts of thirteen plant species belonging to ten families gathered from Albaha region were investigated for their in vitro antileishmanial activity. Table 1 gives the names of the plants, family, parts investigated, voucher specimen numbers, local names, yields in %, and their traditional uses. Results of antileishmanial activity, cytotoxic effects on peritoneal macrophage from BALB/c mice, and selectivity of methanolic extracts studied are summarized in Table 2. Out of the 16 methanol extracts tested against promastigote forms of L. amazonensis, three extracts showed promising activity with potent leishmanicidal activities and good selectivity indices: A. biebersteinii flower (IC50 = 26.9 μg/mL; SI = 5), E. helioscopia leaf (IC50 < 12.5 μg/mL; SI = 8), and S. incanum leaf (IC50 = 18.0 μg/mL; SI = 8). In the case of extracts from Myrrh resin, W. somnifera and aerial parts of P. crispa also showed good antileishmanial activity but a low SI was observed. The rest of extracts tested were either inactive or nonspecific due to high cytotoxicity against normal peritoneal macrophages from BALB/c mice (Table 2). The promising extracts were further tested against intracellular amastigotes of L. amazonensis, and four of these extracts were active (Table 2); in particular the extract of flowers from A. biebersteinii displayed the most promising activity.

Species (part testeda) (μg/mL)
SIe (μg/mL)

A. biebersteinii (Fl)26.9 ± 2.9131.3 ± 6.1513.6 ± 0.6
A. biebersteinii (L)>200
C. procera (L)>200
C. murale (F)>200
Myrrha resin (Re)17.5 ± 0.0149.8 ± 2.03
D. viscosa (L)>200
E. helioscopia (AP)<12.582.5 ± 4.4731.1 ± 3.9
L. dentata (AP)>200
P. crispa (AP)23.5 ± 2.579.0 ± 7.33
P. granatum (Fl)>200
R. chalepensis (L)>200
S. incanum (F)37.8 ± 2.7174.6 ± 6.9524.4 ± 3.0
S. incanum (L)18.0 ± 2.8149.2 ± 3.8831.0 ± 3.8
V. encelioides (L)>200
W. somnifera (F)29.5 ± 1.084.9 ± 4.73
W. somnifera (L)20.3 ± 6.8<12.50

AP, aerial parts; F: fruits; L: leaves; Re: resins; Fl: flowers.
bIC50: Concentration of extract causing 50% growth inhibition.
cSD: Standard deviation.
dCC50: Concentration of extract causing 50% of mortality of peritoneal macrophage from BALB/c.
eSI: Selectivity index. —: Not done.

Phytochemical studies of the genus Achillea have revealed the presence of a number of phytochemicals that exhibited antileishmanial activity. Santos et al. 2010 [17] reported the antileishmanial activity of an essential oil from the leaves and flowers of A. millefolium. Therefore, the antileishmanial activity of A. biebersteinii may be attributed either to the components of the essential oil [17] or alkamides that have been isolated from Achillea species and possess antileishmanial activity [18].

However, E. helioscopia has been the subject of abundant phytochemical and biological investigations, but there are no reports regarding its antileishmanial activity [19]. The plant is used traditionally in Saudi Arabia for removing warts and orally to dispel worms [20]. Several compounds have been isolated from E. helioscopia including jatrophone type diterpenoids and the flavones quercetin, and may be responsible for the leishmanicidal activity of the plant extract [21]. In agreement partially with our results, Duarte et al. reported antileishmanial activity for the stilbene piceatannol isolated from Euphorbia lagascae against promastigotes of L. donovani, L. infantum, and L. major with moderate activity [22]. Several triterpenoids isolated from Euphorbia resinifera and Euphorbia officinarum were found to possess antileishmanial activity [23].

Interestingly, antileishmanial activity was observed for S. incanum leaves. A number of Solanum species with antileishmanial activity have been reported [2428]. It was found that the extract of S. torvum inhibited the proliferation of promastigotes of L. donovani [24]. The fruits of S. stramonifolium were shown to have marginal activity against amastigotes of L. amazonensis [25]. This activity may be attributed to the steroid derivative such as cilistol-A or steroidal alkaloids which form the main compounds in Solanum species [26, 27]. The oleo gum resins (myrrh) of Commiphora species have long been used for health problems such as stomachache, colds, wounds, malaria, fever and as an antiseptic and against skin infections [28]. Previous studies on the Commiphora genus reported no antileishmanial activity of C. parvifolia and C. ornifolia [29]. This is the first report on the antileishmanial activity of myrrh oleo gum resins. Volatile oil of different Commiphora species was found to be rich in beta-elemene, alpha-copaene, alpha-humulene, beta-selinene, and germacrene B. Commiphora oil rich in alpha-humulene may be responsible for antileishmanial activity [28, 30]. Antiplasmodial activities of C. opobalsamum and C. schimperi were previously reported [31].

W. somnifera fruits and leaf (IC50 of 20.3 and 29.5 μg/mL) exhibited, in the present study, more remarkable but nonselective antileishmanial activity than that reported previously and collected from India (IC50: 63.0 μg/mL) [8]. However, similar activity with an extract collected from Oman was reported (IC50: 22.1 μg/mL) [32]. The difference in the activity may be explained in the light of the presence and/or quantities of bioactive compounds in plants that are influenced by several factors including seasons, environment, plant-part used, intraspecies variations, and plant age. It was found that withaferin A, the inhibitor of protein kinase C, is responsible mainly for the higher activity of the plant [8, 33].

In our study, P. crispa extract exhibited more potent antileishmanial activity compared to the P. crispa extract reported in literature [34]. P. crispa species were found to possess antileishmanial activity. P. gnaphalodes essential oil and extract have good leishmanicidal effects and it seems that the leishmanicidal activity has been mostly related to the terpenoid constituents of the plant [35].

4. Conclusion

In conclusion, the evaluation of antileishmanial activity of 16 extracts from 13 plants of Albaha region against L. amazonensis has been reported for the first time and revealed that four extracts were found to have promising antileishmanial phytochemical constituents. In particular, the extract of A. biebersteinii was the most promising extract and should be further investigated using bioactivity-guided isolation of the active constituents. Moreover, the evaluation of antileishmanial activity confirms the ethnobotanical uses of certain plant extracts such as myrrh oleo gum resins and S. incanum.

Conflict of Interests

The authors declare no conflict of interests.


  1. World Health Organization (WHO), Control of the Leishmaniasis: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniasis, WHO, Geneva, Switzerland, 2010.
  2. WHO, “Leishmaniasis,” WHO Fact Sheet 375, 2015, View at: Google Scholar
  3. T. A. Morsy and M. I. Shoura, “Treatment of Saudi Arabian cutaneous leishmaniasis,” Journal of Tropical Medicine and Hygiene, vol. 77, no. 3, p. 68, 1974. View at: Google Scholar
  4. T. T. Amin, H. I. Al-Mohammed, F. Kaliyadan, and B. S. Mohammed, “Cutaneous leishmaniasis in Al Hassa, Saudi Arabia: epidemiological trends from 2000 to 2010,” Asian Pacific Journal of Tropical Medicine, vol. 6, no. 8, pp. 667–672, 2013. View at: Publisher Site | Google Scholar
  5. R. A. Mothana, N. M. Al-Musayeib, M. F. Al-Ajmi, P. Cos, and L. Maes, “Evaluation of the in vitro antiplasmodial, antileishmanial, and antitrypanosomal activity of medicinal plants used in Saudi and Yemeni traditional medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 905639, 7 pages, 2014. View at: Publisher Site | Google Scholar
  6. O. L. Adebayo, D. Suleman, and A. A. Samson, “Natural Products in antileishmanial drug discovery, a review,” Journal of Asian Scientific Research, vol. 3, no. 2, pp. 157–173, 2013. View at: Google Scholar
  7. S. K. Singh, S. Bimal, S. Narayan et al., “Leishmania donovani: assessment of leishmanicidal effects of herbal extracts obtained from plants in the visceral leishmaniasis endemic area of Bihar, India,” Experimental Parasitology, vol. 127, no. 2, pp. 552–558, 2011. View at: Publisher Site | Google Scholar
  8. O. Kayser, A. F. Kiderlen, and S. L. Croft, “Natural products as antiparasitic drugs,” Parasitology Research, vol. 90, no. 2, pp. S55–S62, 2003. View at: Publisher Site | Google Scholar
  9. N. M. Al-Musayeib, R. A. Mothana, S. Al-Massarani, A. Matheeussen, P. Cos, and L. Maes, “Study of the in vitro antiplasmodial, antileishmanial and antitrypanosomal activities of medicinal plants from Saudi Arabia,” Molecules, vol. 17, no. 10, pp. 11379–11390, 2012. View at: Publisher Site | Google Scholar
  10. N. M. Al-Musayeib, R. A. Mothana, A. Matheeussen, P. Cos, and L. Maes, “In vitro antiplasmodial, antileishmanial and antitrypanosomal activities of selected medicinal plants used in the traditional Arabian Peninsular region,” BMC Complementary & Alternative Medicine, vol. 12, article 49, 2012. View at: Publisher Site | Google Scholar
  11. E. Abdel-Sattar, L. Maes, and M. M. Salama, “In vitro activities of plant extracts from Saudi Arabia against malaria, leishmaniasis, sleeping sickness and Chagas disease,” Phytotherapy Research, vol. 24, no. 9, pp. 1322–1328, 2010. View at: Publisher Site | Google Scholar
  12. A. Gashash, Plants in Mountains of Sarah and Alhajaz, Albaha University Publisher, Albaha, Saudi Arabia, 2012.
  13. D. Sladowski, S. J. Steer, R. H. Clothier, and M. Balls, “An improved MIT assay,” Journal of Immunological Methods, vol. 157, no. 1-2, pp. 203–207, 1993. View at: Publisher Site | Google Scholar
  14. A. Dutta, S. Bandyopadhyay, C. Mandal, and M. Chatterjee, “Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis,” Parasitology International, vol. 54, no. 2, pp. 119–122, 2005. View at: Publisher Site | Google Scholar
  15. J. C. Delorenzi, M. Attias, C. R. Gattass et al., “Antileishmanial activity of an indole alkaloid from Peschiera australis,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 5, pp. 1349–1354, 2001. View at: Publisher Site | Google Scholar
  16. E. C. Torres-Santos, D. L. Moreira, M. A. C. Kaplan, M. N. Meirelles, and B. Rossi-Bergmann, “Selective effect of 2′,6′-dihydroxy-4′-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 5, pp. 1234–1241, 1999. View at: Google Scholar
  17. A. O. Santos, A. C. Santin, M. U. Yamaguchi, L. E. R. Cortez, T. Ueda-Nakamura, and C. V. Nakamura, “Antileishmanial activity of an essential oil from the leaves and flowers of Achillea millefolium,” Annals of Tropical Medicine and Parasitology, vol. 104, no. 6, pp. 475–483, 2010. View at: Publisher Site | Google Scholar
  18. J. B. Althaus, M. Kaiser, R. Brun, and T. J. Schmidt, “Antiprotozoal activity of Achillea ptarmica (Asteraceae) and its main alkamide constituents,” Molecules, vol. 19, no. 5, pp. 6428–6438, 2014. View at: Publisher Site | Google Scholar
  19. E. M. Abou-El-Hamd, F. H. Mohamed-Elamir, M. F. M. Moustafa et al., “Euphorbia helioscopia: chemical constituents and biological activities,” International Journal of Phytopharmacology, vol. 3, no. 1, pp. 78–90, 2012. View at: Google Scholar
  20. M. Al-Shanwani, Plants in Saudi Arabia Used for Folk Medicine, King Abdul Aziz City for Science and Technology, 1996.
  21. R. S. Patil, M. S. Patil, S. S. Kshirsagar, P. S. Chaudhari, J. P. Bayas, and R. J. Oswal, “Synthetic and natural products against leishmaniasis—a review,” World Journal of Public Health Sciences, vol. 1, no. 1, pp. 7–22, 2012. View at: Google Scholar
  22. N. Duarte, O. Kayser, P. Abreu, and M. J. U. Ferreira, “Antileishmanial activity of piceatannol isolated from Euphorbia lagascae seeds,” Phytotherapy Research, vol. 22, no. 4, pp. 455–457, 2008. View at: Publisher Site | Google Scholar
  23. N. Mazoir, A. Benharref, M. Bailén, M. Reina, A. González-Coloma, and R. A. Martínez-Díaz, “Antileishmanial and antitrypanosomal activity of triterpene derivatives from latex of two euphorbia species,” Zeitschrift fur Naturforschung C, vol. 66, no. 7-8, pp. 360–366, 2011. View at: Publisher Site | Google Scholar
  24. D. J. Hubert, N. Céline, N. Michel et al., “In vitro leishmanicidal activity of some Cameroonian medicinal plants,” Experimental Parasitology, vol. 134, no. 3, pp. 304–308, 2013. View at: Publisher Site | Google Scholar
  25. Y. Estevez, D. Castillo, M. T. Pisango et al., “Evaluation of the leishmanicidal activity of plants used by Peruvian Chayahuita ethnic group,” Journal of Ethnopharmacology, vol. 114, no. 2, pp. 254–259, 2007. View at: Publisher Site | Google Scholar
  26. V. C. Filho, C. Meyre-Silva, R. Niero et al., “Evaluation of antileishmanial activity of selected brazilian plants and identification of the active principles,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 265025, 7 pages, 2013. View at: Publisher Site | Google Scholar
  27. M. Abreu Miranda, R. F. J. Tiossi, M. R. Dasilva et al., “In vitro leishmanicidal and cytotoxic activities of the glycoalkaloids from Solanum lycocarpum (Solanaceae) fruits,” Chemistry & Biodiversity, vol. 10, no. 4, pp. 642–648, 2013. View at: Publisher Site | Google Scholar
  28. T. Shen, G.-H. Li, X.-N. Wang, and H.-X. Lou, “The genus Commiphora: a review of its traditional uses, phytochemistry and pharmacology,” Journal of Ethnopharmacology, vol. 142, no. 2, pp. 319–330, 2012. View at: Publisher Site | Google Scholar
  29. R. A. Mothana, N. M. Al-Musayeib, A. Matheeussen, P. Cos, and L. Maes, “Assessment of the in vitro antiprotozoal and cytotoxic potential of 20 selected medicinal plants from the island of soqotra,” Molecules, vol. 17, no. 12, pp. 14349–14360, 2012. View at: Publisher Site | Google Scholar
  30. L. Monzote, O. Alarcón, and W. N. Setzer, “Antiprotozoal activity of essential oils,” Agriculturae Conspectus Scientificus, vol. 77, no. 4, pp. 167–175, 2012. View at: Google Scholar
  31. F. A. Abbas, S. M. Al-massarany, S. Khan, T. A. Al-howiriny, J. S. Mossa, and E. A. Abourashed, “Phytochemical and biological studies on Saudi Commiphora opobalsamum L,” Natural Product Research, vol. 21, no. 5, pp. 383–391, 2007. View at: Publisher Site | Google Scholar
  32. M. D. R. Camacho, J. D. Phillipson, S. L. Croft, P. N. Solis, S. J. Marshall, and S. A. Ghazanfar, “Screening of plant extracts for antiprotozoal and cytotoxic activities,” Journal of Ethnopharmacology, vol. 89, no. 2-3, pp. 185–191, 2003. View at: Publisher Site | Google Scholar
  33. N. Sen, B. Banerjee, B. B. Das et al., “Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex,” Cell Death and Differentiation, vol. 14, no. 2, pp. 358–367, 2007. View at: Publisher Site | Google Scholar
  34. J. El-On, L. Ozer, J. Gopas et al., “Antileishmanial activity in Israeli plants,” Annals of Tropical Medicine and Parasitology, vol. 103, no. 4, pp. 297–306, 2009. View at: Publisher Site | Google Scholar
  35. G. R. Asghari, F. Zahabi, A. Eskandarian, H. Yousefi, and M. Asghari, “Chemical composition and leishmanicidal activity of Pulicaria gnaphalodes essential oil,” Research Journal of Pharmacognosy, vol. 1, no. 4, pp. 27–33, 2014. View at: Google Scholar

Copyright © 2015 Saeed S. Al-Sokari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.